


5-BDBD

Cat. No.:	HY-101911		
CAS No.:	768404-03-1		
Molecular Formula:	C ₁₇ H ₁₁ BrN ₂ O ₂		
Molecular Weight:	355.19		
Target:	P2X Receptor		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (175.96 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8154 mL	14.0770 mL	28.1539 mL
	5 mM	0.5631 mL	2.8154 mL	5.6308 mL
	10 mM	0.2815 mL	1.4077 mL	2.8154 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 15% Solutol HS 15 >> 10% Cremophor EL >> 35% PEG 400 >> 40% water
Solubility: 9.8 mg/mL (27.59 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.86 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.86 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

5-BDBD, a potent and selective P2X₄ receptor antagonist, inhibits rP2X₄R-mediated currents, with an IC₅₀ of 0.75 μM. 5-BDBD completely blocks the basal and acute hyperalgesia induced by nitroglycerin (NTG)^{[1][2]}.

IC₅₀ & Target

ISO: 0.75 μM (P2X₄ receptor)

In Vitro

5-BDBD inhibits 10 μM ATP-induced currents of rP2X₄R-expressing HEK293 cells in a concentration-dependent manner, with an IC₅₀ of 0.75 μM^[1].

5-BDBD displaces rightward the ATP concentration-response curve, with an EC₅₀ of 4.7 to 15.9 μM^[1].
5-BDBD could be specifically used to discriminate between P2X1R, P2X2aR, P2X2bR, P2X3R, P2X4R, and P2X7R^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

5-BDBD (28 mg/kg; i.p.; daily for 9 days) can completely block the basal hyperalgesia induced by recurrent NTG injection^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice ^[2]
Dosage:	28 mg/kg
Administration:	i.p.; daily for 9 days
Result:	Prevented NTG-induced mechanical hypersensitivity.

CUSTOMER VALIDATION

- Cell Mol Life Sci. 2022 Aug 16;79(9):483.
- Int Immunopharmacol. 2023 Jun 8;121:110462.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Coddou C, et al. Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor. *Neurosci Lett*. 2019;690:219-224.

[2]. Long T, et al. Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation. *J Neuroinflammation*. 2018;15(1):245. Published 2018 Aug 30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA